⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16428554 | 1.00 | — | — | |
| SCHEMBL14745483 | 0.84 | — | — | |
| SCHEMBL5786961 | 0.84 | — | — | |
| SCHEMBL20745640 | 0.84 | — | — | |
| SCHEMBL2145970 | 0.82 | — | — | |
| SCHEMBL11440898 | 0.80 | CYP2D6 (0.31) | — | |
| SCHEMBL18763434 | 0.76 | — | — | |
| SCHEMBL15751669 | 0.76 | — | — | |
| SCHEMBL11605 | 0.71 | — | — | |
| SCHEMBL18763498 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 407 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023225244-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | BIOGEN MA INC. (US) | 2023-11-23 | — | — | WO | claimed |
| US-20230339976-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. | 2023-10-26 | — | — | US | claimed |
| WO-2023146990-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | claimed |
| WO-2023144053-A1 | HETEROCYCLIC DERIVATIVES | MERCK PATENT GMBH (DE) | 2023-08-03 | — | — | WO | claimed |
| EP-4192585-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-06-14 | — | — | EP | claimed |
| EP-4188920-A1 | PIPERIDIN-1-YL-N-PYRYDINE-3-YL-2-OXOACETAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MTA-ACCUMULATING CANCERS | Tango Therapeutics, Inc. (US) | 2023-06-07 | — | — | EP | claimed |
| US-20220062258-A1 | Heterocyclic derivatives | MERCK PATENT GMBH (DE) | 2022-03-03 | — | — | US | claimed |
| WO-2022026892-A1 | PIPERIDIN-1- YL-N-PYRYDI NE-3-YL-2-OXOACET AM IDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MT A-ACCUMULATING CANCERS | TANGO THERAPEUTICS, INC. (US) | 2022-02-03 | — | — | WO | claimed |
| EP-3914590-A1 | HETEROCYCLIC DERIVATIVES | Merck Patent GmbH (DE) | 2021-12-01 | — | — | EP | claimed |
| WO-2020152067-A1 | HETEROCYCLIC DERIVATIVES | MERCK PATENT GMBH (DE) | 2020-07-30 | — | — | WO | claimed |
| WO-2013149704-A1 | CYCLIC AMIDES AS METAP-2 INHIBITORS | MERCK PATENT GMBH (DE) | 2013-10-10 | — | — | WO | claimed |
| US-8546374-B2 | Amino-tetrazoles analogues and methods of use | ABBVIE INC. (US) | 2013-10-01 | — | — | US | claimed |
| US-20120329772-A1 | AMINO-TETRAZOLES ANALOGUES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2012-12-27 | — | — | US | claimed |
| EP-2527339-A1 | Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof | Abbott Laboratories (US) | 2012-11-28 | — | — | EP | claimed |
| US-8217067-B2 | Antiinflammatory agents, antidepressants, analgesics, purinergic receptor antagonists; neurodegenerative diseases, spinal cord injuries; 1-(2,3-dichlorophenyl)-N-[(2-methylphenyl)methyl]-1H-tetraazol-5-amine | ABBOTT LABORATORIES (US) | 2012-07-10 | — | — | US | claimed |
| US-7704997-B1 | Amino-tetrazole analogues and methods of use | ABBOTT LABORATORIES (US) | 2010-04-27 | — | — | US | claimed |
| US-20070049584-A1 | Amino-tetrazoles analogues and methods of use | ABBVIE INC. | 2007-03-01 | — | — | US | claimed |
| EP-1747206-A1 | AMINO-TETRAZOLES ANALOGUES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2007-01-31 | — | — | EP | claimed |
| US-20060052374-A1 | Amino-tetrazole analogues and methods of use | ABBVIE INC. | 2006-03-09 | — | — | US | claimed |
| WO-2005111003-A1 | AMINO-TETRAZOLES ANALOGUES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2005-11-24 | — | — | WO | claimed |